アルツハイマー病と代謝
Lance A Johnson1,2, Shannon L Macauley1,2,3
1Department of Physiology, University of Kentucky, Lexington, KY 40508 USA.
まとめ
キヌレニン経路を阻害することで,アルツハイマー病のマウスモデルにおける認知機能が回復した. アルツハイマー病の新たな治療策として この経路をターゲットにすることが示唆されています
科学分野:
- 神経科学
- 薬理学について
- 生物化学
背景:
- キヌレニン経路 (KP) は神経炎症と神経変性に関与しています.
- アルツハイマー病 (AD) の病理学では,KPの調節不全が観察されています.
- 特定のKP代謝物はADに関連した認知障害に寄与する可能性があります.
研究 の 目的:
- アルツハイマー病におけるキヌレニン経路阻害の治療の可能性を調査する.
- ADマウスモデルにおける認知障害を逆転させることができるかどうかを判断する.
主な方法:
- 既知のアルツハイマー病のマウスモデルを使用した.
- キヌレニン経路における重要な酵素を標的とする薬理学的阻害剤を投与する.
- 行動テストを用いて認知機能を評価した (例えば,モリスの水迷路,Y迷路).
- 神経炎症とシナプス可塑性のマーカーを 脳組織で分析した
主要な成果:
- キヌレニン経路の阻害により,ADマウスの空間的学習と記憶が有意に改善されました.
- 治療は脳内の神経炎症マーカーの減少につながった.
- KP抑制の後,シナプスタンパク質のレベルが回復することが観察されました.
- 行動改善は脳の生化学的変化と相関しています
結論:
- キヌレニン経路をターゲットにすることで,アルツハイマー病の臨床前モデルにおける認知機能の欠陥を効果的に逆転させる.
- KP阻害は,アルツハイマー病の新たな治療戦略として潜在性を示しています.
- 抗アルツハイマー病の治療の開発には,PK調節剤に関するさらなる研究が必要である.
関連する概念動画
Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Drug Metabolism: Phase I Reactions
3.2K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.2K
Electron Transport Chain: Complex I and II
12.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
12.4K
Drugs Affecting Neurotransmitter Synthesis
1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K
Regulation of Metabolism
9.3K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.3K


